Get Biotech News

United Therapeutics Corporation Announces the 500th Lung Transplant Utilizing its Centralized Ex Vivo Lung Perfusion Service

United Therapeutics Corporation Announces the 500th Lung Transplant Utilizing its Centralized Ex Vivo Lung Perfusion Service

SILVER SPRING, Md. & JACKSONVILLE, Fla.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, and its subsidiary Lung Bioengineering Inc. (LBE) announced that the 500th lung transplant utilizing LBE’s centralized ex vivo lung perfusion (EVLP) service was completed last month. These 500 transplants were the result of evaluating over 800 donated lungs using centralized EVLP since 2014. The 500th transplant was completed in Jacksonville at Mayo Clinic in F

United Therapeutics Corporation Announces the 500th Lung Transplant Utilizing its Centralized Ex Vivo Lung Perfusion Service Read More »

YesCare Providers Honored at Second Annual Louisville Metro Department of Corrections Awards Banquet

YesCare Providers Honored at Second Annual Louisville Metro Department of Corrections Awards Banquet

LOUISVILLE, Ky.–(BUSINESS WIRE)–Two YesCare healthcare providers were honored recently at the second annual LMDC Awards Banquet, honoring excellence in service at the Louisville Metro Department of Corrections. The banquet was held September 7 at University of Louisville’s Alumni Hall. Behavioral Health Director Brittany Elkins was named Mental Health Staffer of the Year, and MAT Nurse Coordinator Stacy Wylie was named Medical Staffer of the Year. The employee-driven, staff-voted awards eveni

YesCare Providers Honored at Second Annual Louisville Metro Department of Corrections Awards Banquet Read More »

Eli Lilly’s Alzheimer’s drug donanemab rejected for NHS use

Eli Lilly’s Alzheimer’s drug donanemab rejected for NHS use

**Eli Lilly’s Alzheimer’s Drug Donanemab Rejected for NHS Use** Eli Lilly’s promising Alzheimer’s treatment, donanemab, has hit a roadblock with the UK’s National Health Service (NHS), which recently chose not to recommend its use. This decision places donanemab in an uncertain position within the UK healthcare system, despite its potential to address unmet needs in

Eli Lilly’s Alzheimer’s drug donanemab rejected for NHS use Read More »

United Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024

United Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its third quarter 2024 financial results before the market opens on Wednesday, October 30, 2024. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, October 30, 2024, at 9:00 a.m. Eastern Time. The webcast will be accessible via

United Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024 Read More »

Dante Omics Awarded Prestigious ISO 9001 Certification for Italian Laboratory

2024-10-23T14:05:41.000Z.png

NEW YORK–(BUSINESS WIRE)–Dante Omics, a trailblazer in genomics-driven artificial intelligence solutions, is proud to announce that its cutting-edge laboratory in Italy has been awarded the internationally recognized ISO 9001:2015 certification for “Provision of genomic Next Generation Sequencing, analysis and interpretation services.” The ISO9001 certification was issued to Dante Labs Srl. This achievement marks a significant step in the company’s commitment to maintaining the highest standa

Dante Omics Awarded Prestigious ISO 9001 Certification for Italian Laboratory Read More »

Scroll to Top